Skip navigation

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Results 1 - 10 of 58 for IMATINIB
  1. ... and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. ... Muller-Tidow C, Reiter A, Koschmieder S. Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome ...
  2. ... and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. ...
  3. ... Schultheis B, Cross NC, Goldman JM. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with ...
  4. Chronic myeloid leukemia is a slow-growing cancer of the blood-forming tissue (bone marrow). Normal bone marrow produces red blood cells (erythrocytes) that carry ...
  5. The ABL1 gene provides instructions for making a protein involved in many processes in cells throughout the body. The ABL1 protein functions as a kinase, ...
  6. The BCR gene provides instructions for making a protein whose function is not completely understood. Studies show that the BCR protein may act as a GTPase ...
  7. The KIT gene provides instructions for making a member of a protein family called receptor tyrosine kinases. Receptor tyrosine kinases transmit signals from ...
  8. Drugs Approved for Leukemia From the National Institutes of Health (National Cancer Institute)  
    Leukemia/Treatments and Therapies ... Leukemia ... National Cancer Institute ... From the National Institutes of Health ... This page lists cancer drugs approved by the FDA ...
  9. Treating Chronic Myeloid Leukemia by Phase (American Cancer Society)  
    Chronic Myeloid Leukemia/Treatments and Therapies ... Chronic Myeloid Leukemia ... American Cancer Society ... Treatment options for chronic myeloid leukemia will depend ...
  10. ... and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. ... Muller-Tidow C, Reiter A, Koschmieder S. Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome ...
previous · 1 · 2 · 3 · 4 · 5 · 6 · next